A trial fibrillation and heart failure: Cause or effect?;Fibrillazione atriale e scompenso cardiaco: Causa o effetto?

Italian Heart Journal Supplement

Volumn 3, Issue 9, 2002, Pages 899-907

  Scardi, Sabino ^a   Mazzone, Carmine ^a  

^a Centro Cardiovascolare   (Italy)

Author keywords

Atrial fibrillation; Heart failure

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; DIGITALIS; DOFETILIDE; FLECAINIDE; IBUTILIDE; PROPAFENONE; QUINIDINE; SOTALOL;

ARTIFICIAL HEART PACEMAKER; CARDIOVERSION; DEFIBRILLATION; DISEASE ASSOCIATION; HEART ARRHYTHMIA; HEART ATRIUM ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART RATE; HIGH RISK PATIENT; HUMAN; REVIEW; THROMBOEMBOLISM; CONGESTIVE HEART FAILURE; HEMODYNAMICS; PATHOPHYSIOLOGY;

ATRIAL FIBRILLATION; HEART FAILURE, CONGESTIVE; HEART RATE; HEMODYNAMIC PROCESSES; HUMANS;

EID: 0242299295     PISSN: 11294728     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (79)

1. Krahn AD, Manfreda J, Tate RB, et al. The natural history of atrial fibrillation: incidence, risk factors and prognosis in the Manitoba follow-up study. Am J Med 1995; 98: 476-84.
2. Kannel WB, Abbott RD, Savage DD, McNamara PM. Epidemiologic features of chronic atrial fibrillation: the Framingham study. N Engl J Med 1982; 306: 1018-122.
3. Johnstone D, Limacher M, Rousseau M, et al. Clinical characteristics of patients in studies of left ventricular dysfunction (SOLVD). Am J Cardiol 1992; 70: 894-900.
4. Khand AU, Gemmell I, Ranckin AC, Cleland JGF. Clinical events leading to the progression of heart failure: insights from a national database of hospital discharges. Eur Heart J 2001; 22: 153-64.
5. Dries DL, Exner DV, Gersh BJ, et al. Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a retrospective analysis of the SOLVD trials. J Am Coll Cardiol 1998; 32: 695-703.
6. Van den Berg MP, Tuinenburg AE, Crijns HJ, et al. Heart failure and atrial fibrillation: current concepts and controversies. Heart 1997; 77: 309-13.
7. Scardi S, Mazzone C. L'anticoagulante nella disfunzione ventricolare sinistra: indicazione allargata o solo in caso di fibrillazione atriale? Giornale di Riabilitazione 1998; 14: 173-9.
8. Middlekauff HR, Stevenson WG, Stevenson LW. Prognostic significance of atrial fibrillation in advanced heart failure. A study of 390 patients. Circulation 1991; 84: 40-8.
9. Carson PE, Johnson GR, Dunkman WB, Fletcher RD, Farrell L, Cohn JN. The influence of atrial fibrillation on prognosis in mild to moderate heart failure. The V-HeFT Studies. The V-HeFT VA Cooperative Studies Group. Circulation 1993; 87 (Suppl VI): 102-10.
10. Likoff MJ, Chandler SL, Kay HR. Clinical determinants of mortality in chronic congestive heart failure secondary to idiopathic dilated of to ischemic cardiomyopathy. Am J Cardiol 1987; 59: 634-8.
11. Stevenson WG, Stevenson LW, Middlekauff HR, et al. Improving survival for patients with atrial fibrillation and advanced heart failure. J Am Coll Cardiol 1996; 28: 1458-63.
12. Natterson PD, Stevenson WG, Saxon LA, Middlekauff HR, Stevenson LW. Risk of arterial embolization in 224 patients awaiting cardiac transplantation. Am Heart J 1995; 129: 564-70.
13. Ciaccheri M, Castelli G, Cecchi F, et al. Lack of correlation between intracavitary thrombosis detected by cross sectional echocardiography and systemic emboli in patients with dilated cardiomyopathy. Br Heart J 1989; 62: 26-9.
14. Dunkman WB, Johnson GR, Carson PE, Bhat G, Farrell L, Cohn JN. Incidence of thromboembolic events in congestive heart failure. The V-HeFT VA Cooperative Studies Group. Circulation 1993; 87 (Suppl VI): 94-101.
15. Cioffi G, Pozzoli M, Forni G, et al. Systemic thromboembolism in chronic heart failure. A prospective study in 406 patients. Eur Heart J 1996; 17: 1381-9.
16. Urbinati S, Pinelli G, Maggioni AP, et al. Rischio embolico e terapia anticoagulante orale nello scompenso cardiaco cronico. G Ital Cardiol 1999; 29: 183-92.
17. The SEOSI Investigators. Survey on heart failure in Italian hospital cardiology units. Results of the SEOSI study. Eur Heart J 1997; 18: 1457-64.
18. The NETWORK Investigators. Clinical outcome with enalapril in symptomatic chronic heart failure: a dose comparison. Eur Heart J 1998; 19: 481-9.
19. Pitt B, Segal R, Martinez FA, on behalf of ELITE Study Investigators. Randomised trial of losartan versus captopril in patients over 65 years with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 1997; 349: 747-52.
20. Doval HC, Nul DR, Grancelli HO, for the Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina (GESICA). Randomised trial of low-dose amiodarone in severe congestive heart failure. Lancet 1994; 344: 493-8.
21. Swedberg K, for the CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987; 316: 1429-35.
22. Cowie MR, Wood DA, Coats AJ, et al. Incidence and aetiology of heart failure; a population-based study. Eur Heart J 1999; 20: 421-8.
23. Mathew J, Hunsberger S, Fleg J, et al. Incidence, predictive factors, and prognostic significance of supraventricular tachyarrthythmias in congestive heart failure. Chest 2000; 118: 914-22.
24. Faggiano P, D'Aloia A, Zanelli E, et al. Contribution of left atrial pressure and dimension to signal-averaged duration in patients with chronic congestive heart failure. Am J Cardiol 1997; 79: 219-22.
25. Pozzoli M, Cioffi G, Traversi E, et al. Predictors of primary atrial fibrillation and concomitant clinical and hemodynamic changes in patients with chronic heart failure: a prospect study in 344 patients with baseline sinus rhythm. J Am Coll Cardiol 1998; 32: 197-204.
26. Pinto YM, Buikema H, Van Gilst WH. Hyperactive tissue renin-angiotensin systems in cardiovascular dysfunction: experimental evidence and clinical hypotheses. Clin Exp Hypertens 1995; 17: 441-68.
27. Yamada T, Fukunami M, Shimonagata T, et al. Prediction of paroxysmal atrial fibrillation in patients with congestive heart failure: a prospective study. J Am Coll Cardiol 2000; 35: 404-13.
28. Tuinenburg AE, Veldhuisen V, Boomsma F, et al. Comparison of plasma neurohormones in congestive heart failure patients with atrial fibrillation versus patients with sinus rhythm. Am J Cardiol 1998; 81: 1207-10.
29. Crozier I, Richards AM, Foy SG, Ikram H. Electrophysiological effects of atrial natriuretic peptide on the cardiac conduction system in man. Pacing Clin Electrophysiol 1993; 16: 738-42.
30. Scardi S, Mazzone C, Goldstein D, et al. SFAAT: studio della fibrillazione atriale cronica non reumatica nell'area triestina: risultati dell'arruolamento. G Ital Cardiol 1995; 25: 173-82.
31. EAFT (European Atrial Fibrillation Trial) Study Group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet 1993; 342: 1255-62.
32. Petersen P, Boysen G, Godtfredsen J, Andersen ED, Andersen B. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study. Lancet 1989; 1: 175-9.
33. Connolly SJ, Laupacis A, Gent M, Roberts RS, Cairns JA, Joyner C. Canadian Atrial Fibrillation Anticoagulation (CAFA) study. J Am Coll Cardiol 1991; 18: 349-55.
34. Stroke Prevention in Atrial Fibrillation Investigators. Stroke Prevention in Atrial Fibrillation study. Circulation 1991; 84: 527-39.
35. Ezekowitz MD, Bridgers SL, James KE, et al. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. N Engl J Med 1992; 327: 1406-12.
36. Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. N Engl J Med 1990; 323: 1505-11.
37. Ruskin J, McHale PA, Harley A, Greenfield JC. Pressure-flow studies in man: effects of atrial systole on left ventricular function. J Clin Invest 1970; 49: 472-8.
38. Shapiro W, Klein G. Alteration in cardiac function immediately following electrical conversion of atrial fibrillation to normal sinus rhythm. Circulation 1968; 38: 1074-84.
39. Gosselink ATM, Crijns HJGM, Van den Berg MP, et al. Functional capacity before and after cardioversion of atrial fibrillation: a controlled study. Br Heart J 1994; 72: 161-6.
40. Van Gelder IC, Crijns HJGM, Blanksma PK, et al. Time course of hemodynamic changes and improvement of exercise tolerance after cardioversion of chronic atrial fibrillation unassociated with cardiac valve disease. Am J Cardiol 1993; 72: 560-6.
41. Naito M, David D, Michelson EL, et al. The hemodynamic consequences of cardiac arrhythmias: evaluation of the relative roles of abnormal atrioventricular sequencing, irregularity of ventricular rhythm and atrial fibrillation in a canine model. Am Heart J 1983; 106: 284-91.
42. Clark DM, Plumb VJ, Epstein AE, Kay GN. Hemodynamic effects of an irregular sequence of ventricular cycle lengths during atrial fibrillation. J Am Coll Cardiol 1997; 30: 1039-45.
43. Daoud EG, Weiss R, Bahu M, et al. Effects of an irregular ventricular rhythm on cardiac output. Am J Cardiol 1996; 78: 1433-6.
44. Shinbane JS, Wood MA, Jensen DN, et al. Tachycardia-induced cardiomyopathy: a review of animal models and clinical studies. J Am Coll Cardiol 1997; 29: 709-15.
45. Fenelon G, Wijn W, Andries E, Brugada P. Tachycardiomyopathy: mechanisms and clinical implications. Pacing Clin Electrophysiol 1996; 19: 95-106.
46. Schumacher B, Luderitz B. Rate issues in atrial fibrillation: consequences of tachycardia and therapy for rate control. Am J Cardiol 1998; 82: 29N-36N.
47. Packer D, Bardy G, Worley S. Tachycardia-induced cardiomyopathy: a reversible form on left ventricular dysfunction. Am J Cardiol 1986; 57: 563-70.
48. Rabbani L, Wang P, Couper G, Friedman WL. Time course of improvement in ventricular function after ablation of incessant automatic atrial tachycardia. Am Heart J 1991; 121: 816-9.
49. Damiano R, Tripp HF, Asano T, et al. Left ventricular dysfunction and dilatation resulting from chronic supraventricular tachycardia. J Thorac Cardiovasc Surg 1987; 94: 135-43.
50. Peters KG, Kienzle MG. Severe cardiomyopathy due to chronic rapidly conducted atrial fibrillation: complete recovery after restoration of sinus rhythm. Am J Med 1988; 85: 242-4.
51. Van Gelder IC, Crijns HJGM, Tieleman RG, et al. Chronic atrial fibrillation: success of serial cardioversion therapy and safety of oral anticoagulation. Arch Intern Med 1996; 156: 2585-92.
52. Atwood JE, Myers J, Sullivan M. The effect of cardioversion on maximal exercise capacity in patients with chronic atrial fibrillation. Am Heart J 1989; 116: 913-8.
53. Spinale FG, Tanaka R, Crawford FA, Zile MR. Changes in myocardial blood flow during development of and recovery from tachycardia-induced cardiomyopathy. Circulation 1992; 85: 717-29.
54. Deedwania PC, Singh BN, Ellenborgen K, et al. Spontaneous conversion and maintenance of sinus rhythm by amiodarone in patients with heart failure and atrial fibrillation. Circulation 1998; 98: 2574-9.
55. Van den Berg MP, Tuinenburg AE, Crijns HJ, et al. Effects of lisinopril in patients with heart failure and chronic atrial fibrillation. J Card Fail 1995; 1: 355-64.
56. Joglar JA, Acusta AP, Shusterman NH, et al. Effect of carvedilol on survival and hemodynamics in patients with atrial fibrillation and left ventricular dysfunction: retrospective analysis of the US Carvedilol Heart Failure Trials Program. Am Heart J 2001; 142: 498-501.
57. Crijns HJ, Van den Berg MP, Van Gelder IC, et al. Management of atrial fibrillation in the setting of heart failure. Eur Heart J 1997; 18 (Suppl C): C45-C49.
58. Van Gelder IC, Crijns HJ, Van Gilst WH, et al. Prediction of uneventful cardioversion and maintenance of sinus rhythm from direct-current electrical cardioversion of chronic atrial fibrillation and flutter. Am J Cardiol 1991; 68: 41-6.
59. Mazzone C, Pandullo C, Scardi S, et al. Left atrial appendage mechanical function after pharmacological or electrical cardioversion in patients with chronic atrial fibrillation: a multicenter, randomized study. Ital Heart J 2000; 1: 128-36.
60. Tieleman RG, De Langen C, Van Gelder IC, et al. Verapamil reduces tachycardia-induced electrical remodeling of the atria. Circulation 1997; 95: 1945-53.
61. Muntinga HJ, Van Den Berg F, Niemeyer MG, et al. Left ventricular diastolic function after electrical cardioversion of atrial fibrillation. Heart 2002; 87: 379-80.
62. Middlekauff HR, Wiener I, Stevenson WG. Low-dose amiodarone for atrial fibrillation. Am J Cardiol 1993; 72: 75F-81F.
63. Capucci A, Villani GQ, Aschieri D, Rosi A, Piepoli MF. Oral amiodarone increases the efficacy of direct-current cardioversion in restoration of sinus rhythm in patients with chronic atrial fibrillation. Eur Heart J 2000; 21: 66-73.
64. Torp-Pedersen C, Moller M, Bloch-Thomsen PE, et al. Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group. N Engl J Med 1999; 341: 857-65.
65. Sticherling C, Hsu W, Tada H, et al. Effects of verapamil and ibutilide on atrial fibrillation and postfibrillation atrial refractoriness. J Cardiovasc Electrophysiol 2002; 13: 151-7.
66. Tuinenburg AE, Van Gelder IG, Van den Berg MP, et al. Lack of prevention of heart failure by serial electrical cardioversion in patients with persistent atrial fibrillation. Heart 1999; 92: 486-93.
67. Haissaguerre M, Marcus FI, Fischer B, Clementy J. Radiofrequency catheter ablation in unusual mechanisms of atrial fibrillation: report of three cases. J Cardiovasc Electrophysiol 1994; 5: 743-51.
68. Santini M, Ricci R, Capucci A, et al. Efficacy of anti-tachypacing therapies and low energy cardioversion in terminating spontaneous atrial tachyarrhythmias in patients with dual implantable defibrillator. (abstr) Eur Heart J 2000; 212 (Suppl): 470.
69. Rawles JM. What is meant by a "controlled" ventricular rate? Br Heart J 1990; 63: 157-61.
70. Scardi S, Humar F, Cesanelli F, et al. L'elettrocardiogramma dinamico nella fibrillazione atriale cronica trattata con digitale. G Ital Cardiol 1991; 21: 503-8.
71. Brignole M, Menozzi C, Gianfranchi L, et al. Assessment of atrioventricular junction ablation and VVIR pacemaker versus pharmacological treatment in patients with heart failure and chronic atrial fibrillation: a randomized controlled study. Circulation 1998; 98: 953-60.
72. Wood MA, Brown-Mahoney C, Kay GN, Ellenbogen KA. Clinical outcomes after ablation and pacing therapy for atrial fibrillation: a meta-analysis. Circulation 2000; 101: 1138-44.
73. Ozcan C, Jahangir A, Friedman PA, et al. Long-term survival after ablation of the atrioventricular node and implantation of a permanent pacemaker in patients with atrial fibrillation. N Engl J Med 2001; 344: 1043-51.
74. Levy T, Walker S, Mason M, et al. Importance of rate control or rate regulation for improving exercise capacity and quality of life in patients with permanent atrial fibrillation and normal left ventricular function: a randomised controlled study. Heart 2001; 85: 171-8.
75. Hohnloser SH, Kuck K H, J Lilienthal, for the PIAF Investigators. Rhythm or rate control in atrial fibrillation. Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trial. Lancet 2000; 356: 1789-94.
76. Crijns HJ, Van Gelder IC. RACE (rate control versus electrical cardioversion for persistent atrial fibrillation). (abstr) Clin Cardiol 2002; 25: 244.
77. Wyse DG. AFFIRM (Atrial Fibrillation Follow-up Investigation of Rhythm Management). (abstr) Clin Cardiol 2002; 25: 243.
78. Bode F, Katchman A, Woosley RL, Franz MR. Gadolinium decreases stretch-induced vulnerability to atrial fibrillation. Circulation 2000; 101: 2200-5.
79. Camm AJ. Future role of electrical therapy for atrial fibrillation: reality for all? Eur Heart J 2001; 3 (Suppl P): P53-P56.